RecruitingEarly Phase 1NCT06684522
Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis
Sponsor
Northwestern University
Enrollment
10 participants
Start Date
Dec 18, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria5
- Individuals age 18-70 years old with eyelid dermatitis for at least two months
- Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib)
- Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib.
- Willing and able participants that provide informed consent
- Willing and able participants that comply with study activities
Exclusion Criteria9
- Self-reported history of allergic response to upadacitinib
- Subject with self-reported history of heart disease, stroke, or neurological conditions
- Currently taking topical medications for eyelid dermatitis within one week of starting study drug
- Women who are pregnant, nursing, or who may become pregnant during the study
- Non-English-speaking subjects
- Patients with an active serious infection
- Patients with active TB or latent TB, patients should be tested for TB prior to upadacitinib treatment.
- Patients with active HBV/HCV or abnormal lab ranges, Lab Data: Hb<8g/dL, ALC<500 cells/mm3 and ANC <1000 cells/mm3
- Patients with a history of malignancy within the last 5 years other than successfully treated NMSC.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGUpadacitinib 15 MG
Upadacitinib 15mg daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06684522